Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/2049| Title: | The authors reply | Authors: | Ramsey, B. W. Elborn, J. S. Wainwright, Claire |
Issue Date: | 2015 | Source: | 373, (18), 2015, p. 1783-1784 | Pages: | 1783-1784 | Journal: | New England Journal of Medicine | Abstract: | L6067364692015-11-10 | DOI: | 10.1056/NEJMc1510466 | Resources: | https://www.embase.com/search/results?subaction=viewrecord&id=L606736469&from=exporthttp://dx.doi.org/10.1056/NEJMc1510466 | | Keywords: | CFTR gene;cost effectiveness analysis;cystic fibrosis;disease exacerbation;drug cost;forced expiratory volume;homozygosity;hospital admission;cystic fibrosis transmembrane conductance regulator;letter;lung disease;priority journal;NCT02390219antibiotic agent;human;dornase alfa;ivacaftor plus lumacaftor;pancreas enzyme | Type: | Article |
| Appears in Sites: | Children's Health Queensland Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.